Market Place
Sourcing Support
Arena BioWorks Lays Off Staff 19 Months After Launch
22 Aug 2025 //
FIERCE BIOTECH
Sarepta Extends $700M Debt to 2030 Amid Elevidys Uncertainty
21 Aug 2025 //
FIERCE BIOTECH
Sarepta Shares More Elevidys Safety Data
19 Aug 2025 //
FIERCE PHARMA
Sarepta Provides New Elevidys Safety Data, Zero Ambulatory Dies
18 Aug 2025 //
BIOSPACE
Sarepta Sells 9M Arrowhead Shares for $174M
13 Aug 2025 //
FIERCE BIOTECH
Arrowhead Redeems $50M Stock, Gets $50M Sarepta Milestone
13 Aug 2025 //
BUSINESSWIRE
Sarepta Advances siRNA Collaboration, Sells Arrowhead Equity
13 Aug 2025 //
BUSINESSWIRE
Arrowhead Emerges as RNAi Knight Amid Sarepta `Downdraft`
12 Aug 2025 //
BIOSPACE
Sarepta Therapeutics Set to Reveal Q2 2025 Financial Results
31 Jul 2025 //
BUSINESSWIRE
FDA Probes 3rd Elevidys Patient Death
28 Jul 2025 //
FIERCE PHARMA
FDA Reverses Stance on Sarepta`s DMD Gene Therapy Elevidys
28 Jul 2025 //
FIERCE PHARMA
FDA Reverses on Sarepta`s DMD Gene Therapy Elevidys
28 Jul 2025 //
FIERCE BIOTECH
Arrowhead Hits $100M Milestone, Awaits Sarepta Payment
28 Jul 2025 //
FIERCE BIOTECH
Sarepta’s Future Uncertain as FDA Eyes New Study for Elevidys
25 Jul 2025 //
BIOSPACE
Arrowhead Reassures investors about pact with troubled Sarepta
24 Jul 2025 //
PRESS RELEASE
Sarepta to Pause Elevidys Gene Therapy Shipments in Us
22 Jul 2025 //
REUTERS
Sarepta Stands Ground Against HHS Request To Stop Shipment
21 Jul 2025 //
BIOSPACE
Sarepta Faces New Scrutiny After 3rd Patient Death
19 Jul 2025 //
FIERCE BIOTECH
FDA Mulls Halting Elevidys Shipments, Sarepta Stock Plunges
18 Jul 2025 //
BIOSPACE
Sarepta Therapeutics Provides Statement on Elevidys
18 Jul 2025 //
BUSINESSWIRE
Sarepta Up 18% After Business Overhaul as Analysts Optimistic
18 Jul 2025 //
BIOSPACE
Sarepta to Cut 500 Jobs, Add Black-Box Warning on Gene Therapy
17 Jul 2025 //
REUTERS
Sarepta Reveals Restructuring Plan and ELEVIDYS Label Update
16 Jul 2025 //
BUSINESSWIRE
Sarepta Announces Grants Under Nasdaq Rule 5635(c)(4)
30 Jun 2025 //
BUSINESSWIRE
FDA Investigates Patient Deaths with Sarepta`s Gene Therapy
25 Jun 2025 //
FDA
Sarepta Stock Falls After Second Death Linked to Gene Therapy
16 Jun 2025 //
REUTERS
Sarepta Updates ELEVIDYS Safety for Non-Ambulatory DMD
16 Jun 2025 //
BUSINESSWIRE
FDA Awards Platform Status to Sarepta SRP-9003 Gene Vector
04 Jun 2025 //
BUSINESSWIRE
Sarepta Updates UK Dosing in Elevidys Study for DMD
21 May 2025 //
BUSINESSWIRE
Sarepta Shows Strong EMBARK Data in Gene Therapy Study
16 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics Shares New Endeavor Results in 2-Year-Olds
16 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics` Elevidys Gene Therapy Approved in Japan
13 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Present at BofA Securities Conference
08 May 2025 //
BUSINESSWIRE
Sarepta sees delays in treatment after Elevidys death report
08 May 2025 //
FIERCE PHARMA
Sarepta Therapeutics Reports Q1 2025 Financials and Updates
06 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Announce Q1 2025 Financial Results
22 Apr 2025 //
BUSINESSWIRE
Sarepta Therapeutics Updates Limb-Girdle Muscular Dystrophy Programs
15 Apr 2025 //
BUSINESSWIRE
Sarepta halts gene therapy studies for muscle disorder
05 Apr 2025 //
REUTERS
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
31 Mar 2025 //
BUSINESSWIRE
Patient dies after receiving Sarepta’s DMD gene therapy Elevidys
19 Mar 2025 //
FIERCE PHARMA
Sarepta Opens Applications For 8th Route 79 Duchenne Scholarship
28 Feb 2025 //
BUSINESSWIRE
Sarepta Announces Q4, Full-Year 2024 Results & Developments
26 Feb 2025 //
BUSINESSWIRE
Sarepta Announces Inaugural $600 M Senior Secured Credit Facility
14 Feb 2025 //
BUSINESSWIRE
Sarepta To Announce Q4 & Full-Year 2024 Results
12 Feb 2025 //
BUSINESSWIRE
Arrowhead & Sarepta Close Global License Agreement
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
10 Feb 2025 //
BUSINESSWIRE
Sarepta`s Embark Study Part 2 Shows Elevidys Benefits In DMD
27 Jan 2025 //
BUSINESSWIRE
Sarepta Therapeutics Reports Q4, Full-Year 2024 Net Revenue
13 Jan 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Present at 43rd J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
31 Dec 2024 //
BUSINESSWIRE
Sarepta Wins 115.2 M US Drug Patent Verdict from Nippon Shinyaku
23 Dec 2024 //
REUTERS
Sarepta Completes Enrollment in SRP-9003 Ph 3 Study for LGMD2E/R4
18 Dec 2024 //
BUSINESSWIRE
FDA`s Accelerated Approval Drives Momentum for Fatal Diseases
02 Dec 2024 //
BIOSPACE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
BUSINESSWIRE
Sarepta, Arrowhead ink $1B-plus deal for seven programs
27 Nov 2024 //
FIERCE BIOTECH
Sarepta axes late-phase DMD drug over safety signal
08 Nov 2024 //
FIERCE BIOTECH
Sarepta`s Elevidys blows sales expectations out of the water
07 Nov 2024 //
FIERCE PHARMA
Sarepta Therapeutics Announces Q3 2024 Results & Developments
06 Nov 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule
31 Oct 2024 //
BUSINESSWIRE
Sarepta Therapeutics Q3 2024 Financial Results Announcement
23 Oct 2024 //
BUSINESSWIRE
